NEOGENOMICS INC 8-K

What Happened

• NeoGenomics, Inc. announced and furnished a press release reporting its results for the first fiscal quarter of 2026 on April 28, 2026 (Item 2.02). The press release is included as Exhibit 99.1 to the Form 8-K and is incorporated by reference, but the company states the release is not “filed” for purposes of Section 18 of the Exchange Act. The Form 8-K was signed by Chief Financial Officer Abhishek Jain.

Key Details

• Event: Press release reporting fiscal Q1 2026 results issued April 28, 2026 (Item 2.02).
• The press release is furnished as Exhibit 99.1 and incorporated by reference in the Form 8-K.
• The company specifies the furnished release is not deemed “filed” under Section 18 of the Securities Exchange Act.
• Form 8-K signature: Abhishek Jain, Chief Financial Officer (signature block included).

Why It Matters

• This filing notifies investors that NeoGenomics has released its quarterly earnings/financial results (earnings, revenue and other quarterly results will be in the press release). Those results can affect the company’s stock price and investor sentiment, so shareholders and prospective investors should review the April 28, 2026 press release for the specific financial figures, trends and any updated guidance. The Form 8-K itself does not present the numeric results—consult Exhibit 99.1 or the company’s investor relations materials for the full financial details.